Stryker Corporation (SYK) FY2025 Earnings Quality Report

Grade: F — Major red flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP — Unqualified opinion (2 critical audit matters: Uncertain Tax Positions; Acquisitions — Inari Medical)

One-line verdict: Stryker earns an F because two checks fail: cash of $4.1B covers only 26% of the $15.9B debt load (C4 critical fail) and goodwill plus intangibles equal 111% of equity (D1 fail). Both fails are the direct consequence of the $4.81B Inari Medical acquisition closed in 2025 plus the Company's long-standing capital allocation preference for acquisitions over cash hoarding. Underneath the flags, Stryker is one of the highest-quality operating businesses in medical technology: 11.2% reported revenue growth, 64.0% gross margin, 19.5% operating margin, $5.0B of operating cash flow, M-Score of -2.62, and clean accruals. EY issued an unqualified opinion and identified two critical audit matters — a $403M unrecognized tax benefit related to a German FCTO assessment of $754M, and the purchase accounting for the Inari acquisition.

A Medtech Powerhouse

Stryker describes itself in the MD&A: "Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually."

The company operates two segments: MedSurg and Neurotechnology, and Orthopaedics. Revenue breakdown from the MD&A:

Two numbers stand out. Vascular grew 50.6% — driven primarily by the Inari Medical acquisition (Inari makes mechanical thrombectomy devices for venous thromboembolism). Spinal Implants revenue collapsed 73.9% because of the Spine business divestiture the company announced in 2024. From the MD&A: "in 2024 we recorded goodwill impairment charges of $456 related to our Spine business and recognized an estimated loss of $362 as a result of classifying certain assets in our Spinal Implants business as held for sale."

From the MD&A: "In 2025 we achieved reported net sales growth of 11.2%. Excluding the impact of acquisitions and divestitures, sales grew 10.3% in constant currency."

Note operating margin of 19.5% in FY2025 vs. 16.3% in FY2024. The FY2024 depression came from the $977M Goodwill and other impairments charge (Spine write-down). Absent those charges, the underlying operating margin has been stable at ~19.5%.

Cash Flow: Elite

Operating cash flow of $5.04B is the highest in this cohort and 92% higher than FY2022 — a 3-year CAGR of 24%. CFFO/NI ratio of 1.55 is excellent, reflecting meaningful depreciation and amortization adjustments plus favorable working capital. Free cash flow of $4.28B comfortably funds the $1.28B annual dividend with plenty left for the $4.96B spent on acquisitions in 2025.

From the MD&A: "In 2025 we completed various acquisitions for total consideration of $4,960, net of cash acquired." The bulk of this was Inari Medical ($4.81B). The "Agreement and Plan of Merger, dated January 6, 2025, by and between Stryker Corporation and Inari Medical, Inc." closed in 2025.

The Balance Sheet: The Inari Effect

Debt grew from $13.6B to $15.9B — an increase of $2.3B to help finance the Inari deal. Cash dropped from $4.5B to $4.1B. The net result: net debt grew $2.7B YoY and goodwill + intangibles jumped by ~$4.5B to $25.0B.

From the MD&A on debt: "In February 2025 we issued $500 of 4.550% senior unsecured notes due February 10, 2027, $700 of 4.700% senior unsecured notes due February 10, 2028, $800 of 4.850% senior unsecured notes due February 10, 2030 and $1,000 of 5.200% senior unsecured notes due February 10, 2035. In the second quarter 2025 we repaid $650 of 1.150% senior unsecured notes and in the fourth quarter 2025 we repaid $750 of 3.375% senior unsecured notes." Total new issuance was $3.0B; total repayment was $1.4B; net new issuance was $1.6B — largely matching the Inari deal financing.

Cash of $4.1B covers 26% of $15.9B debt (C4 fail). Goodwill + intangibles of $25.0B equals 111% of equity (D1 fail).

The 18-Point Screening

Revenue Quality

All three revenue quality checks pass with room. DSO *improved* by 6 days. AR grew only 1.3% against revenue growth of 11.2% — receivables are growing far slower than sales. This is a textbook clean revenue quality profile.

Expense Quality

All four expense quality checks pass. Gross margin of 64.0% is a 260bp premium over the peer median. From the MD&A: "Gross profit as a percentage of net sales increased to 64.0% in 2025 from 63.9% in 2024 primarily due to higher sales pricing and favorable volume partially offset by higher amortization of inventory stepped up to fair value."

Cash Flow Quality

C4 (critical fail): Cash coverage of 26% against debt is below the 30% fail threshold. This is the mechanical result of the Inari-driven debt increase. The other three cash flow checks are cleanly positive.

Balance Sheet

D1 (fail): $25.0B goodwill + intangibles against $22.4B equity = 111% ratio. Stryker's entire M&A history contributes: Wright Medical ($4.0B, 2020), Vocera ($3.1B, 2022), Cerus Endovascular (2023), Inari Medical ($4.8B, 2025), plus a long tail of earlier deals. This is the single clearest D1 fail in this cohort by dollar magnitude.

D2 (pass): Debt/EBITDA of 2.5x is healthy despite the Inari-related increase. Stryker generates enough EBITDA that even the increased debt load remains well-covered on an earnings basis.

M&A Risk

E2: Intangibles change of +23% YoY is above normal but the engine passes it because the Inari acquisition was large and fully disclosed. The 23% growth reflects roughly $4.5B of new intangibles from the deal against a beginning $20.5B base.

Beneish M-Score

M-Score of -2.62 is comfortably clean. Every component is benign: DSRI reflects the AR decline, SGAI reflects stable SG&A ratio, LVGI reflects the modest leverage increase from Inari but within range.

Critical Audit Matters: Two of Them

EY identified two critical audit matters for Stryker — more than typical for a medical device company. This reflects the complexity of (a) an active German tax audit with a large potential assessment and (b) the Inari acquisition purchase accounting.

CAM #1: Uncertain Tax Positions — German FCTO

From the audit report: "As of December 31, 2025, the Company had unrecognized tax benefits of $403. The Company received a final audit report and assessments from the German Federal Central Tax Office (FCTO) related to the years 2010 through 2017 of $754 and expect to receive additional assessments of $11 based on the final audit report."

The potential liability is $754M from the German assessment — larger than Stryker's unrecognized tax benefit reserve of $403M. From the audit report: "Auditing management's evaluation of the uncertain tax positions associated with the FCTO tax assessments was especially challenging due to the level of subjectivity and significant judgment associated with the recognition and measurement of the tax positions."

EY's procedures included "evaluating the assumptions the Company used to assess its uncertain tax positions and related unrecognized tax benefits. We evaluated evidence of management's assessment of the uncertain tax positions related to certain German tax matters. Including inspection of technical memos, inspection of the FCTO tax assessments, and written representations of management. We involved professionals with specialized skill and knowledge to assist in our evaluation of the tax technical merits of the Company's assessments, the amount of the potential benefits to be realized, and the application of relevant tax law."

The $754M potential German assessment is the single largest disclosed tax exposure in this cohort and represents approximately 23% of FY2025 net income. Management has reserved $403M against it. EY has concluded the reserve is appropriately determined under ASC 740.

CAM #2: Acquisitions — Inari Medical Purchase Accounting

From the audit report: "As described in Note 6 to the consolidated financial statements, in 2025 the Company completed the acquisition of Inari Medical, Inc. (Inari) for total consideration of $4,810, net of cash acquired. The acquisition was accounted for as a business combination. Auditing the Company's fair value measurement of certain acquired developed technologies was complex and required significant auditor judgment due to the significant estimation uncertainty in determining the fair value of these intangible assets."

EY explained the judgment: "The Company used an income approach to measure the developed technology intangible assets acquired. The significant assumptions used to estimate the fair value of the intangible assets included discount rates and certain assumptions that form the basis of the forecasted results, including revenue growth rates and profit margins."

EY involved valuation specialists: "We involved our valuation specialists in assisting with the evaluation of methodologies used by the Company and significant assumptions included in the fair value measurements."

The Inari purchase allocation is material because Inari Medical's technology (ClotTriever, FlowTriever) is the primary economic asset acquired — Stryker allocated most of the $4.8B purchase price to developed technology intangibles, which become the amortization base going forward and the future impairment test target.

EY has served as Stryker's auditor since 1974 — a 51-year relationship.

Key Risks from Item 1A

1. Supply chain and sole-source suppliers. From Item 1A: "several raw materials, components, finished devices and services are procured from a sole source due to, among other things, the quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements. If sole-source suppliers or service providers are unable or unwilling to deliver these materials or services... we may not be able to manufacture or have available one or more products during such period of unavailability and our business could suffer, possibly materially."

2. Tariffs. From Item 1A: "recently enacted tariffs by the United States government and retaliatory measures by other governments could adversely impact our supply chain or the availability of certain components." The MD&A echoes: "In 2025 the United States government has announced new tariffs on goods imported into the United States from dozens of countries, including China and the European Union member states."

3. Pricing pressure from cost containment. From Item 1A: "China has implemented a volume-based procurement process designed to decrease prices for medical devices and other products. Pricing pressure has also increased due to pressures on healthcare budgets, continued consolidation among healthcare providers, trends toward managed care."

4. EU MDR compliance. From Item 1A: "the staggered phase-in period for manufacturers to comply with the European Union Medical Device Regulation (MDR) through December 2028" — ongoing compliance cost.

5. Acquisition integration. From Item 1A: "We may be unable to capitalize on previous or future acquisitions... The risks include the activities required and resources allocated to integrate new businesses, a slower pace of integration than initially projected, diversion of management time... the inability to realize the expected benefits, savings or synergies from the acquisition." Inari is the most recent and largest test of this.

6. Geopolitical exposure. Item 1A explicitly lists: "current or potential geopolitical conflicts, such as the tensions between China and Taiwan and the wars in Ukraine and the Middle East."

Altman Z-Score and F-Score

Z-Score of 3.99 is comfortably in the safe zone. The F-Score of 1.54 is slightly elevated — driven primarily by the significant intangibles from the Inari deal inflating the soft assets component of the score. This is an M&A artifact, not a manipulation signal.

Summary

Grade: F. Two fails (C4 critical and D1) drive the grade.

Stryker's F grade is a mechanical result of the Inari Medical acquisition plus its long-standing acquisition-driven growth strategy. Strip away the two balance sheet fails and the company looks pristine: 11.2% revenue growth, 64.0% gross margin, $5.0B CFFO, 1.55 CFFO/NI ratio, DSO declining, AR growing far slower than revenue, clean M-Score, unqualified EY opinion.

C4 (cash vs. debt): The 26% coverage ratio is below threshold but operationally meaningless given Stryker generates $5B of annual cash flow and carries an investment-grade credit profile. Debt/EBITDA of 2.5x is healthy.

D1 (goodwill + intangibles): At 111% of equity, this reflects $25B of accumulated M&A value from Wright Medical, Vocera, Cerus, Inari, and decades of earlier deals. EY's critical audit matter on Inari purchase accounting is specifically about the intangibles that drive this metric.

The real risks are the $754M German FCTO tax assessment (with only $403M reserved), integration of Inari, tariff exposure, and the normal medtech headwinds of pricing pressure, regulatory compliance, and supply chain fragility. None of these are accounting quality concerns. Stryker is one of the cleanest operators in medical technology — the F grade reflects the rules firing on balance sheet structure, not on earnings quality.

**Disclaimer**: This report is based on Stryker's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Fiscal year ended December 31, 2025) + Yahoo Finance

Auditor: Ernst & Young LLP (Unqualified opinion, 2 critical audit matters: Uncertain Tax Positions; Acquisitions — Inari Medical)